Follow
joaquin martinez lopez
Title
Cited by
Cited by
Year
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...
New England Journal of Medicine 375 (8), 754-766, 2016
16422016
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label …
J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ...
The lancet oncology 14 (11), 1055-1066, 2013
10082013
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
9782016
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ...
New England Journal of Medicine 378 (6), 518-528, 2018
9582018
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
N Engl J Med 78 (6), 518-528, 2018
958*2018
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide …
MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ...
The lancet oncology 11 (10), 934-941, 2010
5882010
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ...
Leukemia 31 (10), 2094-2103, 2017
5822017
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ...
Blood, The Journal of the American Society of Hematology 120 (8), 1589-1596, 2012
5542012
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ...
The Lancet Oncology 19 (6), 747-757, 2018
5322018
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
J Martinez-Lopez, JJ Lahuerta, F Pepin, M González, S Barrio, R Ayala, ...
Blood, The Journal of the American Society of Hematology 123 (20), 3073-3079, 2014
4932014
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
BA Thompson, AB Spurdle, JP Plazzer, MS Greenblatt, K Akagi, ...
Nature genetics 46 (2), 107-115, 2014
4842014
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ...
New England Journal of Medicine 387 (6), 495-505, 2022
3872022
Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are …
JJ Lahuerta, MV Mateos Manteca, J Martínez-López, L Rosinol, A Sureda, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
3532008
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation …
B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ...
Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012
3252012
Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ...
New England Journal of Medicine 386 (7), 629-639, 2022
3152022
Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials
JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ...
Journal of clinical oncology: official journal of the American Society of …, 2017
2982017
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ...
Journal of Clinical Oncology 39 (18), 1959, 2021
2872021
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ...
J Clin Oncol 29 (12), 1627-1633, 2011
2842011
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ...
Nature medicine 28 (2), 325-332, 2022
2552022
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
J Martinez-Lopez, J Blade, MV Mateos, C Grande, A Alegre, ...
Blood, The Journal of the American Society of Hematology 118 (3), 529-534, 2011
2472011
The system can't perform the operation now. Try again later.
Articles 1–20